Literature DB >> 27937139

Effects of Aicardi-Goutières syndrome mutations predicted from ADAR-RNA structures.

Andrew J Fisher1,2, Peter A Beal1.   

Abstract

Adenosine (A) to inosine (I) RNA editing is important for life in metazoan organisms. Dysregulation or mutations that compromise the efficacy of A to I editing results in neurological disorders and a shorten life span. These reactions are catalyzed by adenosine deaminases acting on RNA (ADARs), which hydrolytically deaminate adenosines in regions of duplex RNA. Because inosine mimics guanosine in hydrogen bonding, this prolific RNA editing alters the sequence and structural information in the RNA landscape. Aicardi-Goutières syndrome (AGS) is a severe childhood autoimmune disease that is one of a broader set of inherited disorders characterized by constitutive upregulation of type I interferon (IFN) referred to as type I interferonopathies. AGS is caused by mutations in multiple genes whose protein products, including ADAR1, are all involved in nucleic acid metabolism or sensing. The recent crystal structures of human ADAR2 deaminase domain complexed with duplex RNA substrates enabled modeling of how AGS causing mutations may influence RNA binding and catalysis. The mutations can be broadly characterized into three groups; mutations on RNA-binding loops that directly affect RNA binding, "second-layer" mutations that can alter the disposition of RNA-binding loops, and mutations that can alter the position of an α-helix bearing an essential catalytic residue.

Entities:  

Keywords:  ADAR; Aicardi-Goutieres Syndrome; base-flipping; A to I; inosine; RNA editing

Mesh:

Substances:

Year:  2016        PMID: 27937139      PMCID: PMC5324757          DOI: 10.1080/15476286.2016.1267097

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  29 in total

1.  Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2.

Authors:  M Higuchi; S Maas; F N Single; J Hartner; A Rozov; N Burnashev; D Feldmeyer; R Sprengel; P H Seeburg
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

Review 2.  A-to-I RNA editing and human disease.

Authors:  Stefan Maas; Yukio Kawahara; Kristen M Tamburro; Kazuko Nishikura
Journal:  RNA Biol       Date:  2006-01-12       Impact factor: 4.652

3.  RNA-Seq analysis identifies a novel set of editing substrates for human ADAR2 present in Saccharomyces cerevisiae.

Authors:  Tristan Eifler; Subhash Pokharel; Peter A Beal
Journal:  Biochemistry       Date:  2013-10-31       Impact factor: 3.162

Review 4.  ADARs: allies or enemies? The importance of A-to-I RNA editing in human disease: from cancer to HIV-1.

Authors:  Angela Gallo; Franco Locatelli
Journal:  Biol Rev Camb Philos Soc       Date:  2011-06-20

5.  An unwinding activity that covalently modifies its double-stranded RNA substrate.

Authors:  B L Bass; H Weintraub
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

6.  Mice with altered serotonin 2C receptor RNA editing display characteristics of Prader-Willi syndrome.

Authors:  Michael V Morabito; Atheir I Abbas; Jennifer L Hood; Robert A Kesterson; Michelle M Jacobs; David S Kump; David L Hachey; Bryan L Roth; Ronald B Emeson
Journal:  Neurobiol Dis       Date:  2010-04-13       Impact factor: 5.996

Review 7.  ADAR1, inosine and the immune sensing system: distinguishing self from non-self.

Authors:  Brian J Liddicoat; Alistair M Chalk; Carl R Walkley
Journal:  Wiley Interdiscip Rev RNA       Date:  2015-12-21       Impact factor: 9.957

8.  A mammalian RNA editing enzyme.

Authors:  T Melcher; S Maas; A Herb; R Sprengel; P H Seeburg; M Higuchi
Journal:  Nature       Date:  1996-02-01       Impact factor: 49.962

9.  Predicting sites of ADAR editing in double-stranded RNA.

Authors:  Julie M Eggington; Tom Greene; Brenda L Bass
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919

10.  The RNA-editing enzyme ADAR1 controls innate immune responses to RNA.

Authors:  Niamh M Mannion; Sam M Greenwood; Robert Young; Sarah Cox; James Brindle; David Read; Christoffer Nellåker; Cornelia Vesely; Chris P Ponting; Paul J McLaughlin; Michael F Jantsch; Julia Dorin; Ian R Adams; A D J Scadden; Marie Ohman; Liam P Keegan; Mary A O'Connell
Journal:  Cell Rep       Date:  2014-11-13       Impact factor: 9.423

View more
  9 in total

1.  RNA binding candidates for human ADAR3 from substrates of a gain of function mutant expressed in neuronal cells.

Authors:  Yuru Wang; Dong Hee Chung; Leanna R Monteleone; Jie Li; Yao Chiang; Michael D Toney; Peter A Beal
Journal:  Nucleic Acids Res       Date:  2019-11-18       Impact factor: 16.971

2.  Explaining Pathogenicity of Congenital Zika and Guillain-Barré Syndromes: Does Dysregulation of RNA Editing Play a Role?

Authors:  Helen Piontkivska; Noel-Marie Plonski; Michael M Miyamoto; Marta L Wayne
Journal:  Bioessays       Date:  2019-05-20       Impact factor: 4.345

Review 3.  ADAR RNA editing in human disease; more to it than meets the I.

Authors:  Angela Gallo; Dragana Vukic; David Michalík; Mary A O'Connell; Liam P Keegan
Journal:  Hum Genet       Date:  2017-09-14       Impact factor: 4.132

4.  Selective Recognition of RNA Substrates by ADAR Deaminase Domains.

Authors:  Yuru Wang; SeHee Park; Peter A Beal
Journal:  Biochemistry       Date:  2018-02-21       Impact factor: 3.162

Review 5.  RNA Modifications Modulate Activation of Innate Toll-Like Receptors.

Authors:  Isabel Freund; Tatjana Eigenbrod; Mark Helm; Alexander H Dalpke
Journal:  Genes (Basel)       Date:  2019-01-29       Impact factor: 4.096

Review 6.  Innate Viral Sensor MDA5 and Coxsackievirus Interplay in Type 1 Diabetes Development.

Authors:  Samuel I Blum; Hubert M Tse
Journal:  Microorganisms       Date:  2020-07-03

Review 7.  The role of RNA editing enzyme ADAR1 in human disease.

Authors:  Brian Song; Yusuke Shiromoto; Moeko Minakuchi; Kazuko Nishikura
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-06-08       Impact factor: 9.957

8.  ADAR and hnRNPC deficiency synergize in activating endogenous dsRNA-induced type I IFN responses.

Authors:  Anna-Maria Herzner; Zia Khan; Eric L Van Nostrand; Sara Chan; Trinna Cuellar; Ronald Chen; Ximo Pechuan-Jorge; Laszlo Komuves; Margaret Solon; Zora Modrusan; Benjamin Haley; Gene W Yeo; Timothy W Behrens; Matthew L Albert
Journal:  J Exp Med       Date:  2021-07-23       Impact factor: 14.307

9.  Aicardi-Goutières syndrome-associated mutation at ADAR1 gene locus activates innate immune response in mouse brain.

Authors:  Xinfeng Guo; Clayton A Wiley; Richard A Steinman; Yi Sheng; Beihong Ji; Junmei Wang; Liyong Zhang; Tony Wang; Mazen Zenatai; Timothy R Billiar; Qingde Wang
Journal:  J Neuroinflammation       Date:  2021-07-31       Impact factor: 8.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.